Equities

Novoprotein Scientific Inc

688137:SHH

Novoprotein Scientific Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)29.55
  • Today's Change-6.93 / -19.00%
  • Shares traded270.61k
  • 1 Year change-46.47%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,4851,897189
Total Receivables, Net86147101
Total Inventory857737
Prepaid expenses9.41144.41
Other current assets, total4050.000.00
Total current assets2,0702,135332
Property, plant & equipment, net172154153
Goodwill, net------
Intangibles, net19186.71
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets2,2992,333513
LIABILITIES
Accounts payable182124
Accrued expenses111823
Notes payable/short-term debt000.00
Current portion long-term debt/capital leases14148.69
Other current liabilities, total6.891117
Total current liabilities506472
Total long term debt596978
Total debt738387
Deferred income tax----3.21
Minority interest------
Other liabilities, total0.87----
Total liabilities110133153
SHAREHOLDERS EQUITY
Common stock707053
Additional paid-in capital1,9501,940208
Retained earnings (accumulated deficit)16819099
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.180.180.19
Total equity2,1882,200360
Total liabilities & shareholders' equity2,2992,333513
Total common shares outstanding707070
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.